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Dear Editor 
 
Drs ? Goldstein and Sartor1 raise some interesting observations based on the results of our analysis of 
opioid use in the English NHS over a 24 year period. It is important to reiterate that our study2 is an 
observational cohort study and can only provide evidence of association rather than causality. 
ƌ ?ƐGoldstein and Sartor suggest that chronic rather than acute opioid use may be associated with 
disease exacerbation as another potential explanation for our results showing increased morality 
with regular opioid use in the IBD population.  We have shown increased morality with greater than 
3 opioid prescriptions per calender year and a similar Canadian population based study3 showed that 
heavy opioid use (defined as continuous use for 30 days at a dose exceeding 50 mg morphine / day 
or equivalent) was significantly associated with mortality. These results would support but not 
confirm the hypothesis that chronic opiate use exacerbates IBD, but does not show that low dose or 
infrequent use ameliorates disease activity in the IBD population as suggested in their letter. We 
found no potential protective effect for lower strength, or lower dose opiate medications. 
 
Opiate receptors are an attractive target for treating inflammatory bowel disease as they are 
abundant through the GI tract, and have direct effects on motility and potential immunological 
effects. Low dose naltrexone (a µ opioid receptor antagonist when used in higher concentrations) 
has been studied in an RCT ŝŶĂĚƵůƚƌŽŚŶ ?s disease patients compared to placebo by Smith et.al who 
found no statistically significant difference in the proportion of adult patients who achieved clinical 
remission.4 The most recent Cochrane ƌĞǀŝĞǁŽŶƚŚĞƵƐĞŽĨůŽǁĚŽƐĞŶĂůƚƌĞǆŽŶĞŝŶƌŽŚŶ ?ƐĚŝƐĞĂƐĞ
did not find sufficient evidence to make firm conclusions on its efficacy suggesting that further 
randomized controlled trials are needed.5 
 
We agree with Drs ? Goldstein and Sartor that further prospective studies looking at chronic opioid 
use and disease exacerbations would be of interest but would require a large dataset of patients 
followed up for several years to be adequately powered. Given the current evidence of the 
association of mortality with chronic opiate use there would be ethical questions raised on 
continuing these patients on opioid medication (once chronic opioid use has been identified in a 
patient with IBD) making a prospective study difficult to justify. The effect of wound healing and low 
dose opiate therapy would, in our opinion, be best subject to a randomized controlled trial rather 
than looking at observational datasets where wound healing would be unlikely to be objectively and 
reliably assessed. 
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